

1 **Gut microbiota predict *Enterococcus expansion* but not Vancomycin-resistant**

2 ***Enterococcus acquisition***

3 Rishi Chanderraj MD^{1,2}, Christopher A. Brown², Kevin Hinkle², Nicole Falkowski²,

4 Piyush Ranjan², Robert P. Dickson^{2,3,a}, Robert J. Woods^{1,4,a}

5 1. Division of Infectious Diseases, Department of Internal Medicine, University of
6 Michigan Medical School, Ann Arbor, MI, USA.

7 2. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine,
8 University of Michigan Medical School, Ann Arbor, MI, USA.

9 3. Department of Microbiology and Immunology, University of Michigan Medical School,
10 Ann Arbor, MI, USA.

11 4. Computational Medicine and Bioinformatics, University of Michigan Medical School,
12 Ann Arbor, MI, USA.

13 a. These authors contributed equally to this work.

14 **Keywords:** Microbiome, Vancomycin-resistant *Enterococcus*, colonization resistance,
15 hospital-acquired infection

16 **Running title:** Gut microbiota and VRE infection

17 **Summary:** 16S profile of the gut microbiome does not predict VRE acquisition in
18 hospitalized patients, likely due to the rapid and profound microbiota change in this
19 population. VRE expansion and VRE acquisition may be two distinct processes.

20 **Corresponding Author:**

21 Robert Woods

22 5520A MSRB III

23 1150 W. Medical Center Drive

24 Ann Arbor, MI 48109

25 734-647-5899

26 robertwo@med.umich.edu

27 **ABSTRACT**

28 **BACKGROUND:** Vancomycin-resistant *Enterococcus* (VRE) is a leading cause
29 of hospital-acquired infections, and continues to spread despite widespread
30 implementation of pathogen-targeted control guidelines. Commensal gut
31 microbiota provide colonization resistance to VRE, but the role of gut microbiota
32 in VRE acquisition in at-risk patients is unknown.

33 **METHODS:** We performed a case-control study of gut microbiota in hospitalized
34 patients who did (*cases*) and did not (*controls*) acquire VRE. We matched case
35 subjects to control subjects by known risk factors and "time at risk," defined as
36 the time elapsed between admission until positive VRE screen. We characterized
37 gut bacterial communities using 16S rRNA gene amplicon sequencing of rectal
38 swab specimens.

39 **RESULTS:** We analyzed 236 samples from 59 matched case-control pairs. At
40 baseline, case and control subjects did not differ in gut microbiota when
41 measured by community diversity ($p=0.33$) or composition ($p=0.30$). After
42 hospitalization, gut communities of cases and controls differed only in the
43 abundance of the *Enterococcus* containing operational taxonomic unit (OTU),
44 with the gut microbiota of case subjects having more of this OTU than time-
45 matched control subjects ($p=0.01$). Otherwise, case and control communities
46 after the time at risk did not differ in diversity ($p=.33$) or community structure
47 ($p=0.12$). Among patients who became VRE colonized, those having the *Blautia*
48 containing OTU on admission had lower *Enterococcus* relative abundance once
49 colonized ($p =0.004$).

50 **CONCLUSIONS:** The 16S profile of the gut microbiome does not predict VRE
51 acquisition in hospitalized patients, likely due to rapid and profound microbiota
52 change. The gut microbiome does not predict VRE *acquisition*, but may be
53 associated with *Enterococcus expansion*, suggesting that these should be
54 considered as two distinct processes.

55

56 **INTRODUCTION:**

57 Vancomycin-resistant Enterococcus (VRE) is a highly antibiotic-resistant
58 bacteria, is a leading cause of healthcare-associated infections, and is classified
59 as a serious public health threat by the Centers for Disease Prevention and
60 Control[4,5]. Colonization with VRE precedes infection[6,7], and molecular
61 epidemiologic analyses show patient-to-patient hospital transmission is the
62 primary means of spread[8]. Preventing transmission between hospitalized
63 patients is a significant challenge, and despite the widespread application of
64 pathogen-targeted control measures[9], VRE remains endemic in many
65 hospitals[4,5].

66

67 Both indirect human evidence and animal experimentation demonstrate that gut
68 microbiota prevent VRE colonization when a patient is exposed, a phenomenon
69 termed "colonization resistance" [2,10,11]. Colonization resistance may entail
70 competition for resources, secretion of bactericidal factors[3,12], and indirect
71 stimulation of host immune defense mechanisms that target VRE[13,14]. Though
72 colonization resistance plays a crucial role in suppressing VRE expansion and

73 preventing VRE infection[1,15], to date, no study has evaluated whether variation
74 in intestinal microbiota can explain variation in VRE *acquisition* among at-risk
75 patients.

76 To address this gap in our understanding of VRE transmission, we investigated
77 whether the gut microbiome of at-risk patients predicts VRE colonization in a
78 hospitalized patient population. We hypothesized that if the gut microbiome can
79 confer colonization resistance for VRE acquisition, variation in baseline
80 microbiota would explain variation in patient susceptibility to VRE acquisition. To
81 test this hypothesis, we designed a case-control study using 16S rRNA gene
82 amplicon sequencing of rectal swabs acquired from hospitalized patients.

83

84 **METHODS:**

85 **Study setting and design:**

86 We previously conducted a retrospective case-control study of clinical risk factors
87 for VRE acquisition among patients who did (cases) and did not (controls)
88 acquire VRE during their admissions at the University of Michigan Healthcare
89 System from January 2013 until June 2016[16]. We studied gut microbiome
90 communities in 236 rectal swab samples from 59 matched pairs of case and
91 control subjects from patients admitted to the University of Michigan Hospital in
92 2016. 64 out of 118 subjects in this study (54%) were a part of our previous
93 clinical risk factor analysis. The remaining subjects were admitted from June to
94 December 2016 (outside the timeframe of the previous study by six months). The
95 University of Michigan Healthcare system consists of ~1000 inpatient beds and

96 serves as a tertiary referral hospital for southeastern Michigan. The institutional
97 review board at the University of Michigan approved the study before its initiation.

98

99 The infection control practice throughout the study period was to perform routine
100 surveillance for VRE on eight adult units, including intensive care units, the
101 hematology and oncology ward, and the bone marrow transplant ward. All
102 patients were routinely screened on admission and weekly thereafter with rectal
103 swabs that were tested by Bio-Rad VRESelect™ chromogenic medium to detect
104 VRE. Cases were defined as subjects with an initial negative swab followed by a
105 positive swab when evaluated by this selective culture. We further identified the
106 "time at risk" for each case patient, here defined as the time elapsed between
107 admission and positive VRE screen. We matched each case subject to a control
108 subject with an initial negative swab followed by repeat negative swab within the
109 same time at risk (+/- 5%). An additional matching factor was the unit from which
110 the first positive VRE was recovered for cases or the matched swab after the
111 time at risk for controls.

112

113 **Bacterial DNA isolation:**

114 Genomic DNA was extracted from rectal swabs re-suspended in 360 µl ATL
115 buffer (Qiagen DNeasy Blood & Tissue kit) and homogenized in fecal DNA bead
116 tubes using a modified protocol previously demonstrated to isolate bacterial
117 DNA[17,18]. Sterile laboratory water and AE buffer used in DNA isolation were
118 collected and analyzed as potential sources of contamination. ZymoBIOMICS

119 Microbial Community DNA Standard (Zymo Research cat# D6306) was
120 sequenced for error analysis.

121 **16s rRNA gene sequencing**

122 The V4 region of the 16s rRNA gene was amplified using published primers and
123 the dual-indexing sequencing strategy developed previously [17]. Sequencing
124 was performed using the Illumina MiSeq platform (San Diego, CA), using a
125 MiSeq Reagent Kit V2 (500 cycles), according to the manufacturer's instructions
126 with modifications found in the standard operating procedure of the laboratory of
127 Dr. Patick Schloss [17,19]. Accuprime High Fidelity Taq was used in place of
128 Accuprime Pfx SuperMix[20]. Primary PCR cycling conditions were 95°C for two
129 minutes, followed by 20 cycles of touchdown PCR (95°C 20 seconds, 60°C 20
130 seconds and decreasing 0.3 degrees each cycle, 72°C for 5 minutes), then 20
131 cycles of standard PCR (95°C for 20 seconds, 55°C for 15 seconds, and 72°C for
132 5 minutes), and finished with 72°C for 10 minutes.

133

134 **Statistical analyses:**

135 Sequence data were processed and analyzed using the software mothur
136 v.1.43.0[21] according to the standard operating procedure for MiSeq sequence
137 data using a minimum sequence length of 250 base pairs[17,22]. To summarize,
138 the SILVA rRNA database[23] was used as a reference for sequence alignment
139 and taxonomic classification. K-mer searching with 8mers was used to assign
140 raw sequences to their closest matching template in the reference database, and
141 pairwise alignment was performed with the Needleman-Wunsch[24] and NAST

142 algorithms[25]. A k-mer based Naïve Bayesian classifier[26] was used to assign
143 sequences to their correct taxonomy with a bootstrap confidence score threshold
144 of 80. Pairwise distances between aligned sequences were calculated with the
145 method employed by Sogin et al. [27], where pairwise distance equals
146 mismatches, including indels, divided by sequence length. A distance matrix was
147 passed to the OptiCLUST clustering algorithm[28] to cluster sequences into
148 'Operational Taxonomic Units' (OTUs) by maximizing the Matthews Correlation
149 Coefficient with a dissimilarity threshold of 3%[29].

150

151 After clustering and classification of raw sequencing data, we evaluated
152 differences in community structure with Permutational multivariate analysis of
153 variance (PERMANOVA) in the *vegan* package (v 2.0-4)[30] in R (v 3.6.4) [31].
154 We performed resampling of multiple generalized linear models with the
155 *mvabund*[32] package in R to look for individual OTU differences between
156 communities. We set a significance threshold of 0.01 after adjusting for multiple
157 comparisons using a stepdown resampling procedure to reduce the type I error
158 rate[33]. We confirmed individual OTU differences with random forest
159 classification and regression models built with the *ranger* package in R (v 0.11.2)
160 [34]. We used the *caret* (v 6.0-84)[35] package in R for cross-validation and to
161 optimize the hyperparameters of the number of decision trees in the model and
162 the number of features considered by each tree when splitting a node. We
163 corrected for feature importance bias in random forest models with a permutation
164 importance (PIMP) heuristic developed by Altmann et al. [36]. All OTUs were

165 included in diversity and abundance analyses. We performed bivariate analysis
166 with conditional logistic regression using the *survival* (v 3.1-8) package in
167 R[37,38]. Differences in means of final *Enterococcus* abundance in *cases only*
168 were compared with the non-parametric Mann-Whitney U-Test. We used the
169 *vegan* package in R to calculate both the average species diversity in an
170 individual rectal swab (Shannon Diversity) and the change in community
171 structure between initial swab and second swab for each subject (Jaccard
172 Distance). We used Spearman's rank correlation coefficient to determine if
173 Jaccard distance was significantly correlated with the time between swabs, and
174 used non-linear least squares regression to fit a model of Jaccard Distance over
175 time for cases and controls.

176

177 **Adequacy of Sequencing**

178 We performed 16S rRNA gene amplicon sequencing on 236 rectal swab
179 specimens and 15 negative control specimens, which identified 1,188 unique
180 operational taxonomic units (OTUs, genus-level bacterial taxa) at a dissimilarity
181 threshold of 3%. After bioinformatics processing, the mean number of reads per
182 sample was $71,484 \pm 2,684$. No specimens were excluded from the analysis.
183 Rectal swab specimens had clear differences in community structure compared
184 to control specimens, which was confirmed as statistically significant using
185 multiple methods of hypothesis testing [mvabund and PERMANOVA (adonis),
186 $p < 0.01$ both] (**Supplemental figure 1**). Sequences generated from negative
187 control specimens were dominated by a single *Pseudomonas*-classified OTU

188 (OTU001). This OTU was included in all reported analyses, though the exclusion
189 of this OTU did not affect any of the reported results.

190

191 **Data availability**

192 Sequences are available via the NCBI Sequence Read Archive (accession
193 number PRJNA633879). OTU tables, taxonomy classification tables, and
194 metadata tables are available at
195 https://github.com/rishichanderraj/Microbiota_Predictors_VRE_Acquisition.

196

197 **RESULTS:**

198 **Study population and medication exposures**

199 We studied gut microbiome communities in 236 rectal swab samples from 59
200 matched pairs of case and control subjects (**Table 1**). Cases and controls did not
201 differ in demographics (age, sex, ethnicity) nor in the relative frequency of
202 common comorbidities (e.g. immunosuppression, malignancy, or gastrointestinal
203 disease). Antibiotic use was widespread among all subjects and was nearly
204 equal across groups (**Table 2**). Vancomycin, cefepime, metronidazole, and
205 piperacillin-tazobactam were the most commonly used antibiotics in the study
206 population. Cases and controls did not differ significantly in their exposure to any
207 specific antibiotics prior to initial sampling. More cases received proton pump
208 inhibitors prior to initial sampling ($P = 0.04$). During time-at-risk (between initial
209 and subsequent sampling), case and controls did not differ in their exposure to
210 antibiotics or proton pump inhibitors.

211 **Admission gut microbiota do not predict VRE acquisition.**

212 We first compared baseline microbiota across patients who did (*cases*) and did
213 not (*controls*) subsequently acquire VRE. Baseline gut communities of cases and
214 controls did not differ in their community composition, determined either via
215 permutation testing ($p=0.30$ by PERMANOVA) or via visualization (principal
216 component analysis, **Figure 1a**). Similarly, baseline gut communities of cases
217 and controls did not differ in their species diversity as measured by the Shannon
218 diversity index (mean of 2.72 ± 0.90 for controls, mean of 2.71 ± 0.76 for cases,
219 $p=0.96$ for all matched case-control pairs) (**Figure 1b**). We concluded that the
220 gut microbiota, as represented by the 16S profile of these samples of
221 hospitalized patients, do not predict subsequent VRE acquisition.

222

223 **At the time of VRE detection, the gut communities of cases and controls**
224 **differ only in the abundance of *Enterococcus***

225 We next compared gut communities across matched *cases* and *controls* after
226 time-at-risk: after cases had been colonized and time-matched controls had not.
227 After time-at-risk, gut microbiota did differ across *cases* and *controls* ($p < 0.001$,
228 by PERMANOVA), though Shannon diversity index did not (mean of 2.38 ± 0.106
229 for controls, mean of 2.22 ± 0.115 for cases, $p=0.33$ for all matched case-control
230 pairs). The difference in gut microbiota was driven by the increased relative
231 abundance of a single OTU, the *Enterococcus*-classified taxonomic group
232 (OTU0004), which was greater in *cases* than *controls* [$p=0.01$ via *mvabund*,
233 $p < 0.001$ via Random Forest] (**Figure 2**). When this *Enterococcus* OTU was

234 excluded from the analysis, we found no significant difference in communities
235 across cases and *controls* [$p=0.12$ by PERMANOVA] (**Figure 3**). We thus
236 concluded that at the time of VRE acquisition, the gut microbiota of VRE-infected
237 and uninfected patients differ only in the relative abundance of *Enterococcus*,
238 and do not consistently differ in their non-*Enterococcus* microbiota.

239

240 **Gut microbiota change rapidly and profoundly in hospitalized patients**

241 Given the lack of differentiation of gut communities across cases and *controls* at
242 admission and at the time of VRE colonization, we then asked if the temporal
243 change in gut microbiota could distinguish the two groups. We did this by
244 calculating the relative dissimilarity of admission and index (time-at-risk)
245 communities for each subject using Jaccard Distance, a metric of dissimilarity
246 between gut microbial communities measured on a scale of 0 (complete
247 similarity) to 1 (complete dissimilarity, **Figure 4**). The gut communities of both
248 groups underwent a rapid, profound change in composition. Within several days
249 of admission, gut communities of both cases and controls bore little similarity to
250 the communities detected at the time of admission. Size of change in gut
251 communities did not differ across cohorts (0.87 ± 0.016 for cases, 0.86 ± 0.017
252 controls, $p=0.84$). Cases and *controls* also had similar decreases in Shannon
253 diversity (-0.48 ± 0.090 for cases, -0.40 ± 0.077 for controls, $p = 0.93$ for all
254 matched case-control pairs). We found that Jaccard distance was significantly
255 correlated with time (Spearman's rank correlation coefficient $\rho = 0.32$, $p = 0.0006$),
256 and determined that a negative exponential model best fit the data, with gut

257 microbiota approaching complete dissimilarity at an exponential rate of $0.47 * e^{-0.47*t+32}$ (t representing the time between swabs). We found no significant
258 difference in the rate of change between the two groups. We noted that the
259 predicted mean Jaccard distance for two rectal swab samples taken on the same
260 day (t=0) was 0.79 ± 0.058 , implying a substantial amount of variation in
261 community structure within the same day of admission.
262

263

264 **Gut microbiota on admission are associated with *Enterococcus* expansion**

265 Finding no difference in the community composition, diversity, or temporal rate of
266 change across patients who did (*cases*) and did not (*controls*) acquire VRE
267 during their hospitalization, we asked if gut microbiota on admission could predict
268 the relative *abundance* of *Enterococcus* in VRE colonized patients. We restricted
269 our analysis to case subjects and built a random forest regression model to
270 identify taxa present on admission that were predictive of final *Enterococcus*
271 relative abundance. Only *Blautia* and *Lactobacillus* were significant after
272 correcting for multiple testing and feature importance bias (**Figure 5,**
273 **Supplemental Table 1, Supplemental Figure 2**). *Blautia* spp (OTU 0092) on
274 admission was predictive of decreased *Enterococcus* (-10.3% relative
275 abundance adjusted p =0.004 by Mann-Whitney U-test), and *Lactobacillus* spp
276 (OTU 0026) was with an increased abundance of *Enterococcus* after the time at
277 risk (+12.5% relative abundance p =0.007 by Mann-Whitney U-Test). Thus, we
278 found that the presence of specific anaerobes previously implicated in
279 *Enterococcus* colonization resistance[2,15,40] are predictive of decreased

280 *Enterococcus* abundance in VRE colonized patients. These findings suggest that
281 VRE *acquisition* and *Enterococcus expansion* are two distinct processes with
282 different risk factors and pathophysiology.

283

284 **DISCUSSION:**

285 In this study gut microbiota did not predict VRE acquisition in hospitalized
286 patients. Secondary analysis identified individual members of the gut microbiota
287 that do predict *Enterococcus abundance* at the time of VRE acquisition, implying
288 that *acquisition* and *expansion* of VRE may be distinct processes. The
289 community composition, diversity, and temporal rate of change did not differ
290 across patients who did (*cases*) and did not (*controls*) acquire VRE during their
291 hospitalization. As expected based on the study design, gut communities of
292 cases had a greater abundance of *Enterococcus* than controls after the time at
293 risk.

294

295 Gut communities of all subjects demonstrated a rapid and dramatic change
296 during hospitalization that was time-dependent. In this population, antibiotic use
297 was prevalent (Table 2), gut microbial communities were remarkably dynamic
298 (Figure 5), and admission gut microbiota provided very little information about
299 microbiota after the time at risk. Our model of Jaccard distance over time
300 estimated a mean Jaccard distance of 0.79 between two rectal swabs taken on
301 the same day of admission, implying that only 21% of gut microbiota remain
302 constant with resampling within 24 hours. Given the significant correlation

303 between Jaccard distance and time, some of this change is likely due to the
304 disruptive pressures that face gut microbiota upon hospitalization (i.e.,
305 antibiotics). However, a large portion of this change may represent stochasticity
306 and noise introduced by variation in sample collection and storage. These results
307 have important implications for the clinical use of gut microbiota for therapy,
308 prediction, and risk stratification. Given the rapid change of gut communities
309 upon hospitalization, a single static 16S analysis of gut microbiota may miss
310 subtle dynamics important for VRE *acquisition* and is subject to a large amount of
311 noise that may obscure a true biologically meaningful association. Future study of
312 the gut microbiota in VRE *acquisition* may need to move beyond traditional 16S
313 analysis, which can be time-consuming and miss important species-level
314 information [41,42]. Real-time metagenomics and rapid, ultrasensitive
315 quantification technologies hold promise as tools with better resolution to
316 evaluate these processes [43,44].

317

318 Despite the dramatic change in community structure, we did find some evidence
319 of colonization resistance, as admission microbiota *were* predictive of
320 *Enterococcus abundance* at the time of VRE detection. VRE colonized subjects
321 with *Blautia* had less *Enterococcus* expansion, consistent with prior studies
322 [2,15,40]. We hypothesize that there may be a distinction between VRE
323 acquisition and VRE expansion. In conjunction with earlier studies [2,40,45], our
324 findings suggest that commensal anaerobes may play a significant role in
325 suppressing VRE once colonized. In this context, our results further support the

326 possibility of microbiome manipulation to reduce VRE burden even in patients
327 *already colonized* to prevent progression to VRE infection in the individual
328 patient[15,45] or transmission into the surrounding environment and other
329 hospitalized patients[2,10,40].

330

331 In this retrospective case-control study, we controlled for multiple confounders
332 with our time and unit matched design. We used machine learning algorithms
333 robust to multi-collinearity and overfitting, and applied permutation heuristics to
334 correct for feature importance bias and decrease our false discovery rate. This
335 study reveals an opportunity for future studies to delineate key differences in
336 pathophysiology between VRE acquisition and domination.

337

338 In summary, VRE acquisition and expansion may be two distinct processes, and
339 efforts to manipulate the microbiome to prevent the spread of VRE may be more
340 beneficial in reducing VRE domination in colonized patients than in preventing
341 VRE acquisition in un-colonized patients. Future studies of the role of the gut
342 microbiota in VRE acquisition may need to move beyond single time point 16S
343 analyses and address the role of temporal dynamics and stochasticity of gut
344 microbiota in the acquisition and expansion of VRE.

345 **ACKNOWLEDGMENTS:**

346 The authors would like to thank Aline Penkevich for assistance with acquiring
347 rectal swabs for sequencing.

348 The authors have no conflicts of interest to disclose.

349 RC No conflict, CAB No Conflict, KH No Conflict, NF No Conflict, PR No Conflict,
350 RPD No Conflict, RJW No Conflict.

351 **FUNDING:**

352 This work was supported by the National Institutes of Health [grant numbers R01
353 HL144599 to R.P.D, R01 AI143852 to R.J.W, 5T32 HL007749-27 to R.C.]

354

355 1. Bhalla A, Pultz NJ, Ray AJ *et al.* Antianaerobic Antibiotic Therapy Promotes
356 Overgrowth of Antibiotic-Resistant, Gram-Negative Bacilli and Vancomycin-
357 Resistant Enterococci in the Stool of Colonized Patients. *Infect Control Hosp*
358 *Epidemiol* 2003;**24**:644–9.

359 2. Caballero S, Kim S, Carter RA *et al.* Cooperating Commensals Restore
360 Colonization Resistance to Vancomycin-Resistant *Enterococcus faecium*. *Cell*
361 *Host Microbe* 2017;**21**:592-602.e4.

362 3. Kim SG, Becattini S, Moody TU *et al.* Microbiota-derived lantibiotic restores
363 resistance against vancomycin-resistant *Enterococcus*. *Nature* 2019;**572**:665–9.

364 4. Centers for Disease Control U. *Antibiotic Resistance Threats in the United*
365 *States, 2019*.

366 5. Weiner LM, Webb AK, Limbago B *et al.* Antimicrobial-Resistant Pathogens
367 Associated With Healthcare-Associated Infections: Summary of Data Reported to
368 the National Healthcare Safety Network at the Centers for Disease Control and
369 Prevention, 2011–2014. *Infect Control Hosp Epidemiol* 2016, DOI:
370 10.1017/ice.2016.174.

371 6. Zirakzadeh A, Gastineau DA, Mandrekar JN *et al.* Vancomycin-resistant

- 372 enterococcal colonization appears associated with increased mortality among
373 allogeneic hematopoietic stem cell transplant recipients. *Bone Marrow Transplant*
374 2008;**41**:385–92.
- 375 7. Zirakzadeh A, Patel R. Vancomycin-Resistant Enterococci: Colonization,
376 Infection, Detection, and Treatment. *Mayo Clin Proc* 2006;**81**:529–36.
- 377 8. Bonten MJ, Hayden MK, Nathan C *et al.* Epidemiology of colonisation of
378 patients and environment with vancomycin-resistant enterococci. *Lancet*
379 (*London, England*) 1996;**348**:1615–
- 380 9. Fishman N, Infectious Diseases Society of America, Pediatric Infectious
381 Diseases Society. Policy Statement on Antimicrobial Stewardship by the Society
382 for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society
383 of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). *Infect*
384 *Control Hosp Epidemiol* 2012;**33**:322–7.
- 385 10. Ubeda C, Bucci V, Caballero S, *et al.* Intestinal microbiota containing
386 *Barnesiella* species cures vancomycin-resistant *Enterococcus faecium*
387 colonization. *Infect Immun* 2013;**81**:965–73.
- 388 11. Van Der Waaij D, Berghuis-de Vries JM, Lekkerkerk-Van Der Wees JEC.
389 Colonization resistance of the digestive tract in conventional and antibiotic-
390 treated mice. *J Hyg (Lond)* 1971;**69**:405–11.
- 391 12. Buffie CG, Pamer EG. *Microbiota-Mediated Colonization Resistance against*
392 *Intestinal Pathogens.*, 2013:790–801.
- 393 13. Cash HL, Whitham C V., Behrendt CL *et al.* Symbiotic bacteria direct
394 expression of an intestinal bactericidal lectin. *Science (80-)* 2006;**313**:1126–30.

- 395 14. Kobayashi KS, Chamaillard M, Ogura Y *et al.* Nod2-dependent regulation of
396 innate and adaptive immunity in the intestinal tract. *Science* (80-) 2005;**307**:731–
397 4.
- 398 15. Taur Y, Xavier JB, Lipuma L, *et al.* Intestinal Domination and the Risk of
399 Bacteremia in Patients Undergoing Allogeneic Hematopoietic Stem Cell
400 Transplantation. *Clin Infect Dis* 2012;**55**:905–14.
- 401 16. Chanderraj R, Millar JA, Patel TS *et al.* VRE acquisition in a tertiary care
402 hospital: testing the roles of antibiotic use, proton pump inhibitor use, and
403 colonization pressure. *Open Forum Infect Dis* 2019, DOI: 10.1093/ofid/ofz139.
- 404 17. Kozich JJ, Westcott SL, Baxter NT *et al.* Development of a dual-index
405 sequencing strategy and curation pipeline for analyzing amplicon sequence data
406 on the Miseq Illumina sequencing platform. *Appl Environ Microbiol*
407 2013;**79**:5112–20.
- 408 18. Mason KL, Downward JRE, Mason KD *et al.* *Candida albicans* and bacterial
409 microbiota interactions in the cecum during recolonization following broad-
410 spectrum antibiotic therapy. *Infect Immun* 2012;**80**:3371–80.
- 411 19. GitHub - SchlossLab/MiSeq_WetLab_SOP.
- 412 20. Korbie DJ, Mattick JS. Touchdown PCR for increased specificity and
413 sensitivity in PCR amplification. *Nat Protoc* 2008;**3**:1452–6.
- 414 21. Schloss PD, Westcott SL, Ryabin T *et al.* Introducing mothur: Open-source,
415 platform-independent, community-supported software for describing and
416 comparing microbial communities. *Appl Environ Microbiol* 2009;**75**:7537–41.
- 417 22. Schloss PD. MiSeq SOP:mothur. *MiSeq SOP:mothur* 2019.

- 418 23. Quast C, Pruesse E, Yilmaz P, et al. The SILVA ribosomal RNA gene
419 database project: improved data processing and web-based tools. *Nucleic Acids*
420 *Research* 2012. 41: D590-D596.
- 421 24. Needleman SB, Wunsch CD. A general method applicable to the search for
422 similarities in the amino acid sequence of two proteins. *J Mol Biol* 1970;**48**:443–
423 53.
- 424 25. Caporaso JG, Bittinger K, Bushman FD *et al.* PyNAST: a flexible tool for
425 aligning sequences to a template alignment. *Bioinformatics* 2010;**26**:266–7.
- 426 26. Wang Q, Garrity GM, Tiedje JM *et al.* Naïve Bayesian classifier for rapid
427 assignment of rRNA sequences into the new bacterial taxonomy. *Appl Environ*
428 *Microbiol* 2007;**73**:5261–7.
- 429 27. Sogin ML, Morrison HG, Huber JA *et al.* Microbial diversity in the deep sea
430 and the underexplored "rare biosphere." *Proc Natl Acad Sci U S A*
431 2006;**103**:12115–20.
- 432 28. Westcott SL, Schloss PD. OptiClust, an Improved Method for Assigning
433 Amplicon-Based Sequence Data to Operational Taxonomic Units. *mSphere* **2**,
434 DOI: 10.1128/mSphereDirect.00073-17.
- 435 29. Matthews BW. Comparison of the predicted and observed secondary
436 structure of T4 phage lysozyme. *BBA - Protein Struct* 1975;**405**:442–51.
- 437 30. Oksanen J, Blanchet FG, Kindt R *et al.* Vegan: Community Ecology Package.
438 R package version 2.0-2. 2012.
- 439 31. R Development Core Team R. *R: A Language and Environment for Statistical*
440 *Computing.*, 2019.

- 441 32. Wang Y, Naumann U, Wright ST *et al.* Mvabund- an R package for model-
442 based analysis of multivariate abundance data. *Methods Ecol Evol* 2012;**3**:471–
443 4.
- 444 33. ter Braak CJF, Peres-Neto P, Dray S. A critical issue in model-based
445 inference for studying trait-based community assembly and a solution. *PeerJ*
446 2017;**2017**, DOI: 10.7717/peerj.2885.
- 447 34. Wright MN, Ziegler A. Ranger: A fast implementation of random forests for
448 high dimensional data in C++ and R. *J Stat Softw* 2017;**77**, DOI:
449 10.18637/jss.v077.i01.
- 450 35. Kuhn M. Building predictive models in R using the caret package. *J Stat*
451 *Softw* 2008;**28**:1–26.
- 452 36. Altmann A, Toloşi L, Sander O *et al.* Permutation importance: a corrected
453 feature importance measure. *Bioinformatics* 2010;**26**:1340–7.
- 454 37. Therneau T. A Package for Survival Analysis in S. 2015.
- 455 38. Therneau T, Grambsch P. *Modeling Survival Data: Extending the Cox Model*.
456 New York: Springer-Verlag, 2000.
- 457 39. Burnham KP, Anderson DR. Multimodel Inference. *Sociol Methods Res*
458 2004;**33**:261–304.
- 459 40. Donskey CJ, Chowdhry TK, Hecker MT *et al.* Effect of Antibiotic Therapy on
460 the Density of Vancomycin-Resistant Enterococci in the Stool of Colonized
461 Patients. *N Engl J Med* 2000;**343**:1925–32.
- 462 41. Ojima M, Motooka D, Shimizu K *et al.* Metagenomic Analysis Reveals
463 Dynamic Changes of Whole Gut Microbiota in the Acute Phase of Intensive Care

- 464 Unit Patients. *Dig Dis Sci* 2016;**61**:1628–34.
- 465 42. Dubin KA, Mathur D, McKenney PT *et al.* Diversification and Evolution of
466 Vancomycin-Resistant *Enterococcus faecium* during Intestinal Domination. *Infect*
467 *Immun* 2019;**87**, DOI: 10.1128/IAI.00102-19.
- 468 43. Pendleton KM, Erb-Downward JR, Bao Y *et al.* Rapid Pathogen Identification
469 in Bacterial Pneumonia Using Real-Time Metagenomics. *Am J Respir Crit Care*
470 *Med* 2017;**196**:1610–2.
- 471 44. Chanderraj R, Dickson RP. Rethinking pneumonia: A paradigm shift with
472 practical utility. *Proc Natl Acad Sci U S A* 2018;**115**:13148–50.
- 473 45. Ubeda C, Taur Y, Jenq RR *et al.* Vancomycin-resistant *Enterococcus*
474 domination of intestinal microbiota is enabled by antibiotic treatment in mice and
475 precedes bloodstream invasion in humans. *J Clin Invest* 2010;**120**:4332–41.
- 476

477 **Tables**

Table 1. Demographics and Comorbidities of Matched Cohorts

	<i>Controls</i> n = 59	<i>Cases</i> n = 59	<i>P</i> -value
Demographics			
Age (mean ± SE)	57.19 ± 1.62	60.2 ± 1.95	0.23
Female	23 (0.39)	22 (0.38)	0.56
Non-white race	9 (0.15)	9 (0.15)	0.28
Diagnoses and comorbidities			
<i>C. difficile</i> infection	4 (0.07)	11 (0.18)	0.07
Leukemia	21 (0.36)	17 (0.29)	0.38
Lymphoma	12 (0.21)	10 (0.17)	0.49
Bone marrow transplant	15 (0.25)	14 (0.24)	0.64
Solid organ malignancy	35 (0.6)	40 (0.67)	0.33
Metastatic malignancy	29 (0.49)	35 (0.59)	0.10
Diabetes	27 (0.46)	23 (0.39)	0.59
Coronary artery disease	6 (0.11)	10 (0.17)	0.72
Congestive heart failure	19 (0.32)	18 (0.3)	0.60
COPD	21 (0.35)	36 (0.61)	0.02
Peripheral vascular disease	6 (0.1)	2 (0.03)	0.31
End stage renal disease	18 (0.31)	26 (0.44)	0.07
Connective tissue disease	1 (0.01)	4 (0.06)	0.35
Peptic ulcer disease	9 (0.15)	6 (0.11)	0.50
Cirrhosis	2 (0.04)	9 (0.15)	0.06
Cerebrovascular disease	12 (0.21)	17 (0.29)	0.54
Hemiplegia	4 (0.06)	12 (0.2)	0.07
Dementia	1 (0.01)	3 (0.05)	0.34
Charlson Score (mean ± SE)	3.71 ± 0.22	4.45 ± 0.25	0.05

Cases and *controls* were matched by "time at risk" and unit or ward. Values are reported as n (proportion) unless otherwise noted.

478

Table 2. Medication Exposure of Matched Cohorts

Prevalence of exposure

Duration of exposure


	Controls n = 59	Cases n = 59	P value	Controls n = 59	Cases N = 59	P value
Prior to admission swab						
Antibiotics						
Any antibiotics	29 (0.49)	40 (0.68)	0.05	1.72 ± 0.62	2.32 ± 0.47	0.44
Vancomycin	14 (0.24)	21 (0.36)	0.17	0.52 ± 0.3	0.36 ± 0.06	0.61
Metronidazole	8 (0.14)	14 (0.24)	0.17	0.14 ± 0.04	0.4 ± 0.16	0.16
Piperacillin-Tazobactam	8 (0.14)	12 (0.2)	0.29	0.14 ± 0.04	0.21 ± 0.06	0.25
Cefepime	7 (0.12)	11 (0.19)	0.32	0.4 ± 0.3	0.32 ± 0.12	0.81
Proton pump inhibitors	9 (0.15)	19 (0.32)	0.04	0.2 ± 0.07	0.61 ± 0.19	0.07
Between admission and "time at risk" swab						
Antibiotics						
Any antibiotics	56 (0.95)	52 (0.88)	0.18	21.66 ± 4.98	22.36 ± 3.66	0.82
Vancomycin	37 (0.63)	39 (0.66)	0.66	3.55 ± 0.82	3.33 ± 0.82	0.73
Metronidazole	20 (0.34)	24 (0.41)	0.43	2.01 ± 0.72	2.29 ± 0.6	0.75
Piperacillin-Tazobactam	26 (0.44)	25 (0.42)	0.83	3.66 ± 1.13	2.8 ± 0.64	0.42
Cefepime	21 (0.36)	24 (0.41)	0.56	2.92 ± 1.01	3.1 ± 0.82	0.85
Proton pump inhibitors	33 (0.56)	39 (0.66)	0.23	5.15 ± 1.48	6.75 ± 1.32	0.13

Prevalence values are reported as n (proportion). *Duration* values are reported as days of therapy ± SD.


479 **Figures**

480 **Figure 1**

481 **A**



481 **B**




482

483

484 **Figure 1** In Hospitalized patients, admission gut microbiota do not predict
485 subsequent VRE acquisition. We used 16S rRNA sequencing to characterize
486 gut bacterial communities in 118 hospitalized patients who tested negative for
487 VRE at admission. We compared admission gut microbiota across 59 matched
488 cases (patients who acquired VRE) and controls (patients who did not acquire
489 VRE). A Visualization of admission gut microbial communities using Principal
490 Component Analysis. The admission gut communities of cases and controls did
491 not differ in their community composition, either visually or via permutation
492 testing ($P=0.3$, PERMANOVA). B. Comparison of average species diversity as
493 measured by Shannon diversity index in admission gut communities. The
494 admission gut communities of cases and controls did not differ in their community
495 Shannon Diversity index ($p=0.96$, Conditional logistic regression).

496 **Figure 2**




497

498

499 **Figure 2** After the time at risk, the gut microbiota of cases and controls differ
500 primarily in their relative abundance of *Enterococcus*. The ten most abundant
501 bacterial taxa are shown in controls (top) and cases (bottom), at the time of
502 admission (left) and following matched time-at-risk (right). Cases and controls did
503 not differ in their admission microbiota (left). After the time-at-risk, the gut
504 microbiota of cases were enriched with *Enterococcus* relative to control ($P < 0.01$,
505 *mvabund*), but otherwise did not differ in their community composition ($p > 0.05$
506 for all other taxa, *mvabund*).

507 **Figure 3**




508

509

510

511 **Figure 3** With the exception of *Enterococcus*, gut communities of VRE infected
512 and uninfected patients do not differ. When we excluded *Enterococcus* OTU
513 enriched in VRE-infected patients, we found no remaining difference in bacterial
514 community composition, either visually (Principal Component Analysis) or via
515 permutation testing (P = 0.12 PERMANOVA).
516

517 **Figure 4**




518

519

520 **Figure 4** Rapid and dramatic change in gut microbiota among hospitalized
521 patients. We calculated the dissimilarity between admission and subsequent
522 (index, time-at-risk) gut communities in both cohorts with Jaccard distance. Both
523 cases and controls exhibited rapid changes in gut communities during
524 hospitalization, with Jaccard distance changing at an exponential rate. Cases
525 and controls did not differ from each other in temporal disruption of gut
526 microbiota. Dashed lines in the figure represent the 95% confidence interval for
527 predicted mean Jaccard distance (inner ribbon) and predicted Jaccard distance
528 for an individual subject (outer ribbon).
529

530 **Figure 5**
531



532
533

534 **Figure 5** Presence of *Blautia* species on admission is predictive of decreased
535 Enterococcus abundance at the time of VRE acquisition. A random forest
536 regression model identified 7 OTUs present on admission that predicted
537 subsequent relative abundance of *Enterococcus* spp. Of these, the presence of
538 *Enterobacteriaceae* spp., *Lactobacillus* spp., and *Blautia* spp. were significant
539 predictors of final *Enterococcus* spp. relative abundance. Only *Lactobacillus* spp
540 and *Blautia* spp. remained significant after correcting for multiple testing.
541 Significance determined using the Mann-Whitney U test controlled for multiple
542 comparisons.